Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation (original) (raw)

• Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res 902:277–281
  Article PubMed CAS Google Scholar
• Arold S, Sullivan P, Bilousova T et al (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex. Acta Neuropathol 123:39–52
  Article PubMed CAS Google Scholar
• Bales KR, Liu F, Wu S et al (2009) Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29:6771–6779. doi:10.1523/jneurosci.0887-09.2009
  Article PubMed CAS Google Scholar
• Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031. doi:10.1016/s0140-6736(10)61349-9
  Article PubMed Google Scholar
• Benkovic SA, McGowan EM, Rothwell NJ, Hutton M, Morgan DG, Gordon MN (1997) Regional and cellular localization of presenilin-2 RNA in rat and human brain. Exp Neurol 145:555–564. doi:10.1006/exnr.1997.6487
  Article PubMed CAS Google Scholar
• Bernstein HG, Ansorge S, Riederer P, Reiser M, Frolich L, Bogerts B (1999) Insulin-degrading enzyme in the Alzheimer’s disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 263:161–164
  Article PubMed CAS Google Scholar
• Bero AW, Yan P, Roh JH et al (2011) Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 14:750–756. doi:10.1038/nn.2801
  Article PubMed CAS Google Scholar
• Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259
  Article PubMed CAS Google Scholar
• Bramanti V, Tomassoni D, Avitabile M, Amenta F, Avola R (2010) Biomarkers of glial cell proliferation and differentiation in culture. Front Biosci 2:558–570
  Article Google Scholar
• Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344. doi:10.1038/nrn2620
  Article PubMed CAS Google Scholar
• Buckner RL, Snyder AZ, Shannon BJ et al (2005) Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709–7717. doi:10.1523/jneurosci.2177-05.2005
  Article PubMed CAS Google Scholar
• Camus MC, Chapman MJ, Forgez P, Laplaud PM (1983) Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. J Lipid Res 24:1210–1228
  PubMed CAS Google Scholar
• Chakrabarty P, Jansen-West K, Beccard A et al (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 24:548–559. doi:10.1096/fj.09-141754
  Article PubMed CAS Google Scholar
• Cirrito JR, Yamada KA, Finn MB et al (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48:913–922. doi:10.1016/j.neuron.2005.10.028
  Article PubMed CAS Google Scholar
• De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6:99–107
  Article PubMed Google Scholar
• Delledonne A, Kouri N, Reinstatler L et al (2009) Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme. Mol Neurodegener 4:39. doi:10.1186/1750-1326-4-39
  Article PubMed Google Scholar
• Dickson DW, Crystal HA, Mattiace LA et al (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13:179–189
  Article PubMed CAS Google Scholar
• Eckman EA, Adams SK, Troendle FJ et al (2006) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281:30471–30478. doi:10.1074/jbc.M605827200
  Article PubMed CAS Google Scholar
• Fuentealba RA, Liu Q, Zhang J et al (2010) Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 5:e11884. doi:10.1371/journal.pone.0011884
  Article PubMed Google Scholar
• Goedert M (1987) Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer’s disease. EMBO J 6:3627–3632
  PubMed CAS Google Scholar
• Goulinet S, Chapman MJ (1993) Plasma lipoproteins in the golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-I-containing particles. J Lipid Res 34:943–959
  PubMed CAS Google Scholar
• Gupta VB, Laws SM, Villemagne VL et al (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76:1091–1098
  Article PubMed CAS Google Scholar
• Haddy N, De Bacquer D, Chemaly MM et al (2002) The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur J Hum Genet 10:841–850
  Article PubMed CAS Google Scholar
• Holtzman DM, Fagan AM, Mackey B et al (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann Neurol 47:739–747
  Article PubMed CAS Google Scholar
• Iwata N, Tsubuki S, Takaki Y et al (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292:1550–1552. doi:10.1126/science.1059946
  Article PubMed CAS Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128. doi:10.1016/s1474-4422(09)70299-6
  Article PubMed CAS Google Scholar
• Jack CR Jr, Lowe VJ, Weigand SD et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365. doi:10.1093/brain/awp062
  Article PubMed Google Scholar
• Jack CR Jr, Wiste HJ, Vemuri P et al (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 133:3336–3348
  Article PubMed Google Scholar
• Jiang Q, Lee CY, Mandrekar S et al (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58:681–693. doi:10.1016/j.neuron.2008.04.010
  Article PubMed CAS Google Scholar
• Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer’s amyloid-beta. J Neurosci 32:16458–16465. doi:10.1523/jneurosci.3987-12.2012
  Article PubMed CAS Google Scholar
• Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G (2011) Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci 31:1644–1651. doi:10.1523/jneurosci.5491-10.2011
  Article PubMed CAS Google Scholar
• Kim J, Jiang H, Park S et al (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci 31:18007–18012. doi:10.1523/jneurosci.3773-11.2011
  Article PubMed CAS Google Scholar
• Klunk WE, Price JC, Mathis CA et al (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174–6184. doi:10.1523/jneurosci.0730-07.2007
  Article PubMed CAS Google Scholar
• Koffie R, Hyman B, Spires-Jones T (2011) Alzheimer’s disease: synapses gone cold. Molecular Neurodegeneration 6:63
  Article PubMed Google Scholar
• Koffie RM, Hashimoto T, Tai HC et al (2012) Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135:2155–2168
  Article PubMed Google Scholar
• Koffie RM, Meyer-Luehmann M, Hashimoto T et al (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106:4012–4017. doi:10.1073/pnas.0811698106
  Article PubMed CAS Google Scholar
• Koistinaho M, Lin S, Wu X et al (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10:719–726. doi:10.1038/nm1058
  Article PubMed CAS Google Scholar
• Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785–9793
  PubMed CAS Google Scholar
• Leissring MA, Farris W, Chang AY et al (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40:1087–1093
  Article PubMed CAS Google Scholar
• Marquez-Sterling NR, Lo AC, Sisodia SS, Koo EH (1997) Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci 17:140–151
  PubMed CAS Google Scholar
• May P, Rohlmann A, Bock HH et al (2004) Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol 24:8872–8883. doi:10.1128/mcb.24.20.8872-8883.2004
  Article PubMed CAS Google Scholar
• Meilandt WJ, Cisse M, Ho K et al (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29:1977–1986. doi:10.1523/jneurosci.2984-08.2009
  Article PubMed CAS Google Scholar
• Miller BC, Eckman EA, Sambamurti K et al (2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 100:6221–6226. doi:10.1073/pnas.1031520100
  Article PubMed CAS Google Scholar
• Mooijaart SP, Berbee JF, van Heemst D et al (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3:9
  Article Google Scholar
• Moore AH, O’Banion MK (2002) Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease. Adv Drug Deliv Rev 54:1627–1656
  Article PubMed CAS Google Scholar
• Moore BD, Chakrabarty P, Levites Y et al (2012) Overlapping profiles of Abeta peptides in the Alzheimer’s disease and pathological aging brains. Alzheimers Res Ther 4(3):18
  Article PubMed CAS Google Scholar
• Morris JC, Roe CM, Xiong C et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122–131. doi:10.1002/ana.21843
  Article PubMed CAS Google Scholar
• Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? J Neurochem 1:167–185
  Article Google Scholar
• Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754–760
  Article PubMed CAS Google Scholar
• Page K, Hollister R, Tanzi RE, Hyman BT (1996) In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc Natl Acad Sci USA 93:14020–14024
  Article PubMed CAS Google Scholar
• Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91:10625–10629
  Article PubMed CAS Google Scholar
• Pocivavsek A, Burns MP, Rebeck GW (2009) Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57:444–453. doi:10.1002/glia.20772
  Article PubMed Google Scholar
• Reiman EM, Chen K, Liu X et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 106:6820–6825. doi:10.1073/pnas.0900345106
  Article PubMed CAS Google Scholar
• Riddell DR, Zhou H, Atchison K et al (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28:11445–11453
  Article PubMed CAS Google Scholar
• Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842. doi:10.1038/nm1782
  Article PubMed CAS Google Scholar
• Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489–1499. doi:10.1172/jci10498
  Article PubMed CAS Google Scholar
• Shigematsu K, McGeer PL, McGeer EG (1992) Localization of amyloid precursor protein in selective postsynaptic densities of rat cortical neurons. Brain Res 592:353–357
  Article PubMed CAS Google Scholar
• Sokolow S, Luu SH, Nandy K et al (2012) Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer’s disease cortex. Neurobiol Dis 45:381–387
  Article PubMed CAS Google Scholar
• Suh J, Lyckman A, Wang L, Eckman EA, Guenette SY (2011) FE65 proteins regulate NMDA receptor activation-induced amyloid precursor protein processing. J Neurochem 119:377–388
  Article PubMed CAS Google Scholar
• Sullivan PM, Han B, Liu F et al (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32:791–801
  Article PubMed CAS Google Scholar
• Takahashi RH, Milner TA, Li F et al (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869–1879
  Article PubMed CAS Google Scholar
• Takami K, Terai K, Matsuo A, Walker DG, McGeer PL (1997) Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer’s disease brains. Brain Res 748:122–130
  Article PubMed CAS Google Scholar
• Thal DR (2012) The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol 236:1–5
  Article PubMed CAS Google Scholar
• Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
  Article PubMed Google Scholar
• Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615–29619. doi:10.1074/jbc.R800019200
  Article PubMed CAS Google Scholar
• Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741
  Article PubMed CAS Google Scholar
• Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR (2011) Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J Neurosci 31:11328–11337
  Article PubMed CAS Google Scholar
• Villemagne VL, Ataka S, Mizuno T et al (2009) High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 66:1537–1544. doi:10.1001/archneurol.2009.285
  Article PubMed Google Scholar
• Villemagne VL, Pike KE, Chetelat G et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192
  Article PubMed CAS Google Scholar
• Vlassenko AG, Vaishnavi SN, Couture L et al (2010) Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci USA 107:17763–17767. doi:10.1073/pnas.1010461107
  Article PubMed CAS Google Scholar
• Wenk GL (2003) Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry 9:7–10
  Google Scholar